

"Antimicrobial Resistance and Syndromic Management of STIs

> AA HOOSEN Department of Medical Microbiology University of Pretoria



STI PATHOGENS

BACTERIA

- Neisseria gonorrhoeae
- Chlamydia trachomatis
- Treponema pallidum
- Haemophilus ducreyi
- Klebsiella granulomatis
- Gardnerella vaginalis
 Ureaplasma urealyticum
 Mycoplasma hominis
 Mycoplasma genitalium

VIRUSES

- HSV
- HPV
- HBV

PARASITES

Trichomonas vaginalis

FUNGUS

Candida albicans

What have we learned from sexually transmitted infection research in sub-Saharan Africa?

David Mabey, Francis Ndowa, Ahmed Latif

Sex Transm Infect 2010;86:488-492

ABSTRACT

Many of the most important research findings on STIs in the past 30 years have come from sub-Saharan Africa. African researchers and their international collaborators have led the way in the development and validation of syndromic STI management, in furthering our understanding of the interactions between HIV and other STIs, in the development of evidence-based strategies for the control of HIV and other STIs in high risk groups and in the general population, and in clinical, microbiological and epidemiological studies on syphilis, chancroid and ophthalmia neonatorum. This review summarises the major achievements of STI researchers in Africa in the past 30 years, and discusses the reasons underlying the success of STI research in Africa.



SYNDROMIC MANAGEMENT of STIs

A series of evaluations of the syndromic management flowcharts was commissioned by WHO and UNAIDS in the 1990s, and the results were published as a supplement in Sexually Transmitted Infections in 1998.

Of the 16 study sites, 10 were in Africa. The main conclusions from these studies were that the flowcharts for urethral discharge and genital ulcer are reasonably sensitive and specific, whereas the flowchart for vaginal discharge is neither sensitive nor specific



WHY SYNDROMIC

ADVANTAGES

- 1. Treatment at point of first contact
- 2. Treatment is immediate
- 3. Efficient, comprehensive and good quality
- 4. Does not require specialists
- 5. Laboratory tests not needed
- 6. Can be implemented at different settings; Family Planning Clinic, Antenatal Clinic, etc.
- 7. Allows more time for counseling and contact management (4Cs)



WHY SYNDROMIC

DISADVANTAGES

- 1. Over treatment in some cases
- 2. Compliance of treatment
- 3.Asymptomatic infections not detected



Protocols for the management of a person with a



According to the Essential Drugs List





Directorate: HIV/AIDS and STDs Department of Health, Private Bog X828, Prateria 0001 Tel: (012) 312-0121 Fee: (012) 326-2801

June 1998



National
 Department of
 Health
 guidelines
 developed in
 1996

 Revision 2009 (resistance in GC & emergence of HSV)

FIRST LINE COMPREHENSIVE MANAGEMENT AND CONTROL OF SEXUALLY TRANSMITTED INFECTIONS (STIs)

Protocol for the management of a person with a Sexually Transmitted Infection

According to the Essential Drug List

Chapter 12 Sexually transmitted infections Chapter 12: Sexually transmitted infections

- 12.1 Lower abdominal pain (LAP)
- 12.2 Vaginal discharge syndrome (VDS)
- 12.3 Male urethritis syndrome (MUS)
- 12.4 Scrotal swelling (SSW)
- 12.5 Genital ulcer syndrome (GUS)
- 12.6 Bubo
- 12.7 Balanitis/balanoposthitis (BAL)
- 12.8 Syphilis serology and treatment
- 12.9 Treatment of more than one STI syndrome
- 12.10 Genital molluscum contagiosum (MC)


12.11 Genital warts (GW) Condylomata Accuminata

12.12 Pubic lice (PL)




ADULT MALE URETHRAL DISCHARGE

Neisseria gonorrhoeae	<mark>40 – 95</mark> %
 Ceftriaxone, cefixime, spectinomycin 	
Chlamydia trachomatis	+/- 20 %
 Tetracyclines, macrolides, azithromycin 	
Mycoplasma genitalium	4 – 16%
 Macrolides, azithromycin 	
Trichomonas vaginalis	3 – 5 %
 Metronidazole; tinidazole 	
Ureaplasma urealyticum	1- 5 %
 Tetracycline; azithromycin 	





Neisseria gonorrhoeae





Neisseria gonorrhoeae: Which agents?

Ceftriaxone & cefixime – currently used

Spectinomycin


- If parenteral treatment is preferred, spectinomycin seems suitable, although isolates with decreased susceptibility to spectinomycin have been reported
- Spectinomycin bind to the ribosome and interferes with protein synthesis.

Resistance

 Resistance to spectinomycin usually occurs via a single-step chromosomal mutation, resulting in high-level resistance



Chlamydia trachomatis





Antibiotic resistance in Chlamydiae


Kelsi M Sandoz¹ and Daniel D Rockey^{1,†}

¹ Molecular & Cellular Biology Program & the Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, OR 97331–4804, USA

Abstract

There are few documented reports of antibiotic resistance in *Chlamydia* and no examples of natural and stable antibiotic resistance in strains collected from humans. While there are several reports of clinical isolates exhibiting resistance to antibiotics, these strains either lost their resistance phenotype *in vitro*, or lost viability altogether. Differences in procedures for chlamydial culture in the laboratory, low recovery rates of clinical isolates and the unknown significance of heterotypic resistance observed in culture may interfere with the recognition and interpretation of antibiotic resistance. Although antibiotic resistance has not emerged in chlamydiae pathogenic to humans, several lines of evidence suggest they are capable of expressing significant resistant phenotypes. The adept ability of chlamydiae to evolve to antibiotic resistance *in vitro* is demonstrated by contemporary examples of mutagenesis, recombination and genetic transformation. The isolation of tetracycline-resistant *Chlamydia suis* strains from pigs also emphasizes their adaptive ability to acquire antibiotic resistance genes when exposed to significant selective pressure.

GENITAL MYCOPLASMAS





Mycoplasma genitalium

- Smallest self-replicating prokaryote
- Lacks cell wall
- Genome of only 580 kilobase pairs
- Charcteristic pear/flask shaped morphology with terminal tip organelle for attachment
- Role in disease difficult to establish difficult to grow in culture, long duration, low yield
- Molecular assays led to number of studies (qualitative & quantitative)
- Studies developed countries show an association between *M genitalium* and male urethritis



MATERIALS AND METHODS

Specimens:

- Urine specimens from men attending a private practitioner in Pretoria
- **300** men presenting with urethral signs & symptoms
 - Visible discharge (94)
 - Burning on micturition (206)

75 asymptomatic men








- At least 1 pathogen detected in 138 (46%) patients
- Urethral organisms detected :
 - In symptomatic men (n=300): MG was detected in 52 (17.3%) NG in 50 (16.7%) CT in 37 (12.3%) TV in 24 (8.0%)
 - In asymptomatic men (n=75): MG was detected in 5 (6.6%) (p = 0.03) CT in 4 (5.1%) (p = 0.04) NG in 2 (2.6%) (p<0.001) TV in 1 (1.3%) (p = 0.03)



BACTERIAL LOAD





Мусорlasma genitalium TREATMENT

- Lacks cell wall beta-lactams inherent resistance
- Susceptible to those that inhibit protein synthesis
- CDC guidelines macrolides, tetracyclines
 & flouroquinolones
- Cannot determine MIC because not easy to culture & intra-cellular location
- Clinical trials test of cure by detection of organism, bacterial load






- Hannan 1998 in-vitro study showed susceptibility to azithromycin but not doxycycline & ciprofloxacin
- Falk 2003, Swedish study where patients were re-tested after 4-5 weeks tetracycline did not eradicate *M* genitalium & azithromycin was more active
- Bradshaw et al 2006, Australian study reported significant treatment failure with single dose Azithromycin (resistance to macrolides) & infection cleared with 400mg moxifloxacin for 10 days.
- Bjournelius et al 2008 recommend 500mg Azithromycin first day followed by 250mg for 4 days for treatment failures



Trichomonas vaginalis





VAGINAL DISCHARGE AND LOWER ABDOMINAL PAIN

CERVICAL DISCHARGE

- Nesseria gonorrhoeae
- Chlamydia trachomatis

VAGINAL DISCHARGE

- Trichomonas vaginalis
- Candida albicans
- Gardnerella vaginalis (BACTERIAL VAGINOSIS



Bosseman EA, et al. Utility of antimicrobial susceptibility of in *Trichomonas vaginalis-infected* women with clinical treatment failure. Sexually Transmitted Diseases 2011; 38: 983-7

- Nitro-imidazole resistance 2-6% suggested in USA
- Women who had failed at least 2 courses of standard therapy Alternate treatment based on susceptibility testing
- Clinical & microbiologic cure rates were higher for women treated according to results of in-vitro tests compared to lower dose of different drug



Trichomonas vaginalis Local Study

- For MIC & MLC: All isolates tested were considered to be susceptible (CLSI guidelines: MIC ≤ 32 μ g/ml, MLC ≤ 50 μ g/ml)
- Generally values obtained under aerobic conditions were similar to values obtained anaerobically- differences observed were minimal
- Metronidazole remains an appropriate agent for treatment of trichomoniasis

LIMITATIONS

■ No reference ATCC strain with known MIC or MLC was available

CONSIDERATIONS

In vitro values of metronidazole susceptibility are only indicators of the degree of sensitivity or resistance of a specific trichomonad isolate under fixed laboratory conditions






EPIDEMIOLOGY OF GENITAL ULCER DISEASE

SYPHILIS	40%	HERPES	60%
CHANCROID	40%	SYPHILIS	30%
HERPES	15%		15%
LGV	3%	■ LGV	15%
GI/DONOVAN	1%	GI/DONOVAN	1%



Protocol for the management of a person with a Sexually Transmitted Infection

GENITAL ULCER SYNDROME (GUS)





- Studies conducted in Mwanza, Tanzania, also demonstrated high prevalence rates of HSV infection: 50% of women and 25% of men were HSV-2 seropositive by the age of 25 years.(1)
- Other studies confirmed the high prevalence of HSV-2 in other African countries. (2)
- The importance of HSV-2 in facilitating the sexual transmission of HIV was demonstrated in a case control study of HIV seroconverters in the Mwanza cohort, which found that 22% of new HIV infections in women and 74% in men could be attributed the co-factor effect of HSV-2. (3)
- Unable to show impact on HIV with suppressive treatment
- 1. Obasi A, Mosha F, Quigley M, et al. Antibody to herpes simplex virus type 2 as a marker of sexual risk behavior in rural Tanzania. J Infect Dis 1999;179:16-24.
- 2. Orroth KK, Freeman EE, Bakker R, et al. Understanding the differences between contrasting HIV epidemics in east and West Africa: results from a simulation model of the Four Cities Study. Sex Transm Infect 2007;83(Suppl 1):i5-16.
- 3. del Mar Pujades Rodri´guez M, Obasi A, Mosha F, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002;16:451-62.



Macrolide-resistance testing and molecular subtyping of Treponema pallidum strains from South Africa Etienne E Müller, Gabriela Paz Bailey, David A Lewis ISSTDR 2011 ABSTRACT

Objectives

To determine whether the main 23S rRNA mutation (A2058G) that confers macrolide resistance in *Treponema pallidum* is present among DNA obtained from syphilitic ulcers in South Africa and to determine the strain subtype distribution using molecular methods.

Results

None of the samples analysed contained the 23S rRNA gene point mutation that confers macrolide resistance. A total of 8 *arp* repeat sizes, 8 RFLP patterns and a combined total of 17 subtypes were identified in this study population. The most common subtypes were 14d (43%), followed by 17d (13%), 14b (7%), 22b (5%) and 23b (5%).



CHALENGES WITH DRUG RESISTANT STIS

- Diverse aetiological agents bacteria, viruses, protozoan
- Some organisms cannot be cultured/difficult to culture on artificial media
- Intracellular location
- Mixed infections in high-risk behaviour populations
- Management strategies such as syndromic management
- Impact of HIV



ACKNOWLEDGEMENTS

- Lucy Fernandes
- Marcelle Le Roux
- Babsie de Villiers
- Yusuf Dangor
- AAdam
- Post-graduate students
- Laboratory staff Medunsa/DGM & UP-TAD

